Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00:01 2023-01-27 pm EST
189.35 USD   -2.01%
04:39pInsider Sell: Moderna
MT
10:21aOmicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDC
RE
01/26FDA advisers back the same COVID vaccine for initial shots, boosters
RE
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Britain is little better prepared for future pandemics - Former UK vaccine chief

11/30/2022 | 08:08am EST
People queue outside a private coronavirus disease (COVID-19) testing facility, amid the COVID-19 outbreak, in central London

LONDON (Reuters) - Britain is only marginally better prepared for another pandemic than it was for COVID-19, the former head of Britain's vaccine taskforce said on Wednesday, criticising how some structures that helped it emerge from the pandemic had been dismantled.

Britain has one of the highest coronavirus death tolls in the world with more than 177,000 deaths, although its rapid procurement and deployment of vaccines helped the government lift lockdown restrictions sooner than some others.

Kate Bingham, who procured Britain's COVID vaccines in 2020, said there was now no leadership on preparing for possible new variants and some manufacturing capacity had been mothballed.

"We've got the capabilities and yet systematically things are being dismantled that we put in place," Bingham told lawmakers on Wednesday.

"I don't think we're in a much better place to deal with a new pandemic. I think we're marginally better."

Bingham said more work was need to improve the ability of vaccines to stop transmission of newer COVID-19 variants, and she did not know why an agreement for more vaccines from Moderna, agreed in June, had not been signed.

"I absolutely welcome the concept of a big relationship with Moderna to provide and bring both R&D and manufacturing to the UK. So that I'm very positive about. I haven't seen it happen," she said. "It just seems odd that nothing has yet been signed."

Junior health minister Neil O'Brien said that because the broad agreement reached with Moderna in June included more flexibility and open-endedness, the deal was complicated to close.

"Because we are buying a flexible tool, that is a fundamentally complication negotiation... we are extremely close to finalising the remaining detail," O'Brien told lawmakers.

"We have agreed the substantive bulk of all that needs to be agreed, and we are now chasing down the detail."

(Reporting by Alistair Smout; editing by William James)

By Alistair Smout


ę Reuters 2022
All news about MODERNA, INC.
04:39pInsider Sell: Moderna
MT
10:21aOmicron sub-variant XBB.1.5 accounts for 61.3% of U.S. COVID cases - CDC
RE
01/26FDA advisers back the same COVID vaccine for initial shots, boosters
RE
01/26FDA's advisers back plan to simplify COVID-19 vaccinations
AQ
01/26Moderna's Reported Plan to Increase COVID-19 Vaccine Price Raised Concerns From US Sena..
MT
01/26Novavax needs 6 months to produce annual COVID shots that match new variants
RE
01/25Updated COVID vaccines prevented illness from latest variants -CDC
RE
01/25Cowen Adjusts Price Target on Moderna to $150 From $130, Maintains Market Perform Ratin..
MT
01/25Lonza underscores growth prospects with share buy-back, dividend hike
RE
01/24Morgan Stanley Adjusts Moderna Price Target to $205 From $209, Maintains Equal Weight R..
MT
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 073 M - -
Net income 2022 8 725 M - -
Net cash 2022 12 352 M - -
P/E ratio 2022 9,04x
Yield 2022 -
Capitalization 74 239 M 74 239 M -
EV / Sales 2022 3,24x
EV / Sales 2023 7,51x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 193,24 $
Average target price 228,88 $
Spread / Average Target 18,4%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Paul Burton Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.7.49%74 239
LONZA GROUP AG17.19%42 748
IQVIA HOLDINGS INC.11.53%42 445
ALNYLAM PHARMACEUTICALS, INC.-3.63%28 492
SEAGEN INC.8.70%25 936
CELLTRION, INC.3.93%19 184